Vita Therapeutics Strengthens Leadership to Advance Multiple Technology Platforms


New senior management and board additions draw on scientific, regulatory, manufacturing and business expertise

BALTIMORE, March 22, 2022–(BUSINESS WIRE)–Vita Therapeutics, a cellular engineering company that harnesses the power of genetics to develop cellular therapies to treat muscular dystrophies and solid tumors, today announced the hiring of Amy Wesa, PhD, as Senior Vice President of Preclinical and Translational Research, Alexandra (Xana) Capela, PhD, as Senior Vice President of IND Regulatory and Strategy, and Michael Kuo as Vice Senior President of Manufacturing. Additionally, Brown Advisory’s Chief Financial Officer and COO, David M. Churchill, was recently appointed to the Vita Therapeutics Board of Directors.

“I am thrilled that we continue to attract top executive talent like Amy, Xana and Michael to the Vita team as we grow our research, regulation and manufacturing towards our ultimate goal of helping people who have need new medical treatments,” said Douglas Falk, MS, Chief Executive Officer. “Additionally, I am very pleased to welcome David to our Board of Directors. His leadership roles at Brown Advisory will serve our business well as he brings knowledge and perspective to our growing infrastructure.”

Dr. Wesa has 20 years of post-doctoral experience in immuno-oncology and cell and gene therapy and has led research and development strategy for clinical translation from discovery to product development to phase I clinical trials Dr. Wesa is the former Vice President of Research and Development at Champions Oncology and has held leadership positions at Intrexon and Celsense. She is a former faculty member of the University of Pittsburgh School of Medicine and holds a doctorate in cancer biology from Wayne State University’s School of Medicine.

Dr. Capela is a neurobiologist with over 20 years of post-doctoral and industrial experience developing cell therapies for neurodegenerative disorders, most recently as a preclinical and regulatory consultant. Previously, she was a member of the management team of StemCells, Inc. for 15 years. Dr. Capela received his PhD in Biomedical Sciences from Albany Medical College/University of Porto.

Mr. Kuo, MT (ASCP) has over 24 years of experience developing novel cell, gene and regenerative medicine therapies to support early to late stage clinical trials. He previously served as Senior Vice President of Technical Operations at MANA Therapeutics. Prior to joining MANA, Mr. Kuo was Vice President of Quality and Operations at MaxCyte, where he was responsible for overseeing the development of new platform technology products, as well as providing operational leadership for CMC to support the first IND-sponsored human clinical trial of MaxCyte in solid cancers. . Mr. Kuo also served as Senior Manager of Quality Assurance at Mesoblast and held various leadership positions at CMC throughout his career. He has established and led numerous GMP compliant manufacturing, quality assurance, and analytical testing operations and has overseen clinical manufacturing, process development, translational scale-up, technology transfer, and analytical testing. in the world’s leading contract manufacturing and development organizations and contract test labs. Mr. Kuo earned his BSc in Medical Technology and Microbiology and his certification in Biomedical Regulatory Affairs from the University of Washington.

Mr. Churchill is a partner, chief financial officer and chief operating officer at Brown Advisory. With a focus on building world-class teams and a strong organizational culture, Mr. Churchill’s leadership extends to the community, where he serves on several not-for-profit boards. Having held various financial and operational management positions throughout his career, he thrives in growing entrepreneurial businesses. His background in finance, management and operations can be found at Brown Advisory where he oversees all non-investment related areas. He joined Brown Advisory in 1997 and co-led Brown Advisory’s management buyout deal from Bankers Trust.

About Vita Therapeutics

Vita Therapeutics is a biotechnology company generating cutting-edge cell therapies for the treatment of debilitating neuromuscular diseases and cancers. Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace defective ones in patients. The Company is advancing its co-lead VTA-100 and VTA-300 programs for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors to file investigational drug applications with the Food and Drug Administration in the United States in 2023. In the long term, the Company is developing these proprietary cell therapies using a dual development strategy starting with autologous-derived cells before moving to a hypoimmunogenic universal cell line. Vita Therapeutics has completed $32 million in Series A funding and is currently working with numerous partners, including PanCella, Wyss Institute and Johns Hopkins University, to advance clinical programs. To learn more about the company, visit

See the source version on


Mike Beyer
Sam Brown Inc. Healthcare Communications
[email protected]

Source link


Comments are closed.